Lisinopril or carvedilol in prevention of trastuzumab-induced cardiotoxicity in patients with HER2-positive early stage breast cancer: Longitudinal changes of left ventricular ejection fraction below normal levels (LVEF <50%).

Pamela N. Munster,Roy N. Tamura,Jeffrey P. Krischer,Worta McCaskill-Stevens,Maya Guglin

Lisinopril or carvedilol in prevention of trastuzumab-induced cardiotoxicity in patients with HER2-positive early stage breast cancer: Longitudinal changes of left ventricular ejection fraction below normal levels (LVEF <50%).

2021

Pamela N. Munster
Roy N. Tamura
Jeffrey P. Krischer
Worta McCaskill-Stevens
Maya Guglin

509Background: Treatment of HER2-positive breast cancer patients with trastuzumab is highly effective. However, a trastuzumab-associated decline in the left ventricular ejection fraction (LVEF) and...

Keywords:

Ejection fraction
Medicine
Internal medicine
in patient
Trastuzumab
Carvedilol
Cardiology
Cardiotoxicity
Stage (cooking)
Breast cancer
Lisinopril

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations